PD-L1 expression in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.

被引：0
|
作者：
Mamesaya, Nobuaki
Kenmotsu, Hirotsugu
Miyawaki, Eriko
Kotake, Mie
Kawamura, Takahisa
Kobayashi, Haruki
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e20530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20530
引用
收藏
页数：2
相关论文
共 50 条
  • [21] PD-L1 heterogeneity in patients with non-small cell lung cancer
    Wei, Zhigang
    Fan, Linlin
    Yang, Xia
    Li, Jie
    Zhan, Xuemei
    Ye, Xin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (05) : E268 - E274
  • [22] PD-L1 immunohistochemistry in patients with non-small cell lung cancer
    Jotatsu, Takanobu
    Oda, Keishi
    Yatera, Kazuhiro
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S2127 - S2129
  • [23] Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
    Paz-Ares, L.
    Spira, A.
    Raben, D.
    Planchard, D.
    Cho, B. C.
    Ozguroglu, M.
    Daniel, D.
    Villegas, A.
    Vicente, D.
    Hui, R.
    Murakami, S.
    Spigel, D.
    Senan, S.
    Langer, C. J.
    Perez, B. A.
    Boothman, A-M
    Broadhurst, H.
    Wadsworth, C.
    Dennis, P. A.
    Antonia, S. J.
    Faivre-Finn, C.
    ANNALS OF ONCOLOGY, 2020, 31 (06) : 798 - 806
  • [24] Prognostic significance of PD-L1 in stage II/III non-small cell lung cancer.
    Tural, Deniz
    Karaca, Mustafa
    Akar, Emre
    Okay, Damla
    Cil, Ibrahim
    Akyurek, Nalan
    Uner, Aytug
    Ozet, Ahmet
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] The influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.
    Nindra, Udit
    Stevens, Samuel Xavier
    Shahnam, Adel
    Pal, Abhijit
    Adam, Tamiem
    Yip, Po Yee
    Lee, Jenny Hj
    Boyer, Michael J.
    Nagrial, Adnan
    Kao, Steven Chuan-Hao
    Bray, Victoria Jane
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18810 - E18810
  • [26] PD-L1 expression in different samples of non-small cell lung cancer
    Kovacevic, M.
    Kern, I.
    VIRCHOWS ARCHIV, 2017, 471 : S104 - S104
  • [27] Chemoradiotherapy combined with ICIs in the treatment of high PD-L1 expression-sensitive patients with non-small cell lung cancer
    Zhu, Qi
    Fang, Henghu
    Zhang, Yuan
    Zheng, Wei
    Wu, Shanshan
    Wen, Juyi
    JOURNAL OF RADIATION RESEARCH AND APPLIED SCIENCES, 2025, 18 (02)
  • [28] PD-L1 Expression and Molecular Alterations in Non-Small Cell Lung Cancer
    Ebare, K.
    Song, W.
    Opitz, L.
    Rosca, O.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (03): : S52 - S53
  • [29] PD-L1 expression: An emerging biomarker in non-small cell lung cancer
    Adam, Julien
    Planchard, David
    Marabelle, Aurelien
    Soria, Jean-Charles
    Scoazec, Jean-Yves
    Lantuejoul, Sylvie
    ANNALES DE PATHOLOGIE, 2016, 36 (01) : 94 - 102
  • [30] PD-L1 expression is associated with advanced non-small cell lung cancer
    Chen, Zhiquan
    Mei, Jiandong
    Liu, Lunxu
    Wang, Guochen
    Li, Zuosheng
    Hou, Jingpu
    Zhang, Qiuyang
    You, Zongbing
    Zhang, Liu
    ONCOLOGY LETTERS, 2016, 12 (02) : 921 - 927
12345